Cloxacillin

立即咨询

Cloxacillin

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	61-72-3
规格:	≥98%

包装与价格：

包装	价格(元)
10mg	电议
25mg	电议
50mg	电议
100mg	电议

产品介绍

理化性质和储存条件

Molecular Formula: C19H18ClN3O5S;

Molecular Weight: 435.88

Synonym: HSDB-3042; Cloxacillin; HSDB3042; HSDB 3042

Chemical Name: 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((3-(2-chlorophenyl)-5-methyl-4-isoxazolyl)carbonyl)amino)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta))-

InChi Key: LQOLIRLGBULYKD-JKIFEVAISA-N

InChi Code: InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1

SMILES Code: O=C([C@@H](C(C)(C)S[C@]1([H])[C@@H]2NC(C3=C(C)ON=C3C4=CC=CC=C4Cl)=O)N1C2=O)O

In Vitro	Cloxacillin (HSDB-3042) (0-2048 μg/mL; 20-24 h) shows good antibacterial activity for S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL[1]. Cloxacillin (0.015625 μg/mL; 6 h) inhibits the hemolytic activity of Hlα in vitro, and this inhibition is not only more pronounced when combined with TZ and TZ, but also suppresses the inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins[1]. Cell Viability Assay[1] Cell Line: S. aureus 8325-4, S. aureus DU1090 (an Hlα-deleted strain) Concentration: 0-2048 μg/mL Incubation Time: 20-24 h Result: Inhibited S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL. Western Blot Analysis[1] Cell Line: S. aureus 8325-4 Concentration: 0.015625 μg/mL (combines with Thioridazine (TZ, 0.25 μg/mL) and Tetracycline (TC, 0.03125 μg/mL)). Incubation Time: 6 h Result: Inhibited the expression of Hlα and the inhibition was more pronounced when combined with TZ and TC. Western Blot Analysis[1] Cell Line: RAW264.7 cells (exposes to S. aureus 8325-4/DU1090 or pure Hlα) Concentration: 0.015625 μg/mL (combines with TZ (0.25 μg/mL) and TC (0.03125 μg/mL)). Incubation Time: 6 h Result: Inhibited the activation of MAPKs, NF-кB and NLRP3-related proteins thereby inhibiting the inflammatory response when combined with TC and TZ.
In Vivo	Cloxacillin (HSDB-3042) (1.6125 mg/kg; s.c.; 12-h intervals for 72 h) protects mice from S. aureus peritonitis in vivo when combines with Thioridazine and Tetracycline[1]. Cloxacillin (7.5 mg/per; i.p.; twice daily from day 3 for 3 days) develops less severe synovitis and reduces bone erosions when combines with anti-IL-15 antibodies[3]. Animal Model: Female BALB/c mice (6-week-old; peritonitis model)[1]. Dosage: 1.6125 mg/kg (combines with TC (3.125 mg/kg) and TZ (25 mg/kg)) Administration: Subcutaneous injection; 12-h intervals for 72 h. Result: Reduced the degree of inflammatory cell infiltration in the mouse lung tissue and alveolar structures tended to be normal. Significantly reduced the pathological changes in spleen and liver tissue, as well as decreased the CFU counts of S. aureus in the peritoneal cavity. Animal Model: Female wildtype C57BL/6 mice (8-week-old; systemic S. aureus-induced arthritis model) Dosage: 7.5 mg/per (combines with 25 μg/per anti-IL-15 antibodies) Administration: Intraperitoneal injection; twice daily from day 3 (after bacterial inoculation) and stopped at day 6. Result: Showed activities of reducing severe synovitis and bone erosions when combined with anti-IL-15 antibodies.

In Vitro

Cloxacillin (HSDB-3042) (0-2048 μg/mL; 20-24 h) shows good antibacterial activity for S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL[1]. Cloxacillin (0.015625 μg/mL; 6 h) inhibits the hemolytic activity of Hlα in vitro, and this inhibition is not only more pronounced when combined with TZ and TZ, but also suppresses the inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins[1]. Cell Viability Assay[1] Cell Line: S. aureus 8325-4, S. aureus DU1090 (an Hlα-deleted strain) Concentration: 0-2048 μg/mL Incubation Time: 20-24 h Result: Inhibited S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL. Western Blot Analysis[1] Cell Line: S. aureus 8325-4 Concentration: 0.015625 μg/mL (combines with Thioridazine (TZ, 0.25 μg/mL) and Tetracycline (TC, 0.03125 μg/mL)). Incubation Time: 6 h Result: Inhibited the expression of Hlα and the inhibition was more pronounced when combined with TZ and TC. Western Blot Analysis[1] Cell Line: RAW264.7 cells (exposes to S. aureus 8325-4/DU1090 or pure Hlα) Concentration: 0.015625 μg/mL (combines with TZ (0.25 μg/mL) and TC (0.03125 μg/mL)). Incubation Time: 6 h Result: Inhibited the activation of MAPKs, NF-кB and NLRP3-related proteins thereby inhibiting the inflammatory response when combined with TC and TZ.

In Vivo

Cloxacillin (HSDB-3042) (1.6125 mg/kg; s.c.; 12-h intervals for 72 h) protects mice from S. aureus peritonitis in vivo when combines with Thioridazine and Tetracycline[1]. Cloxacillin (7.5 mg/per; i.p.; twice daily from day 3 for 3 days) develops less severe synovitis and reduces bone erosions when combines with anti-IL-15 antibodies[3]. Animal Model: Female BALB/c mice (6-week-old; peritonitis model)[1]. Dosage: 1.6125 mg/kg (combines with TC (3.125 mg/kg) and TZ (25 mg/kg)) Administration: Subcutaneous injection; 12-h intervals for 72 h. Result: Reduced the degree of inflammatory cell infiltration in the mouse lung tissue and alveolar structures tended to be normal. Significantly reduced the pathological changes in spleen and liver tissue, as well as decreased the CFU counts of S. aureus in the peritoneal cavity. Animal Model: Female wildtype C57BL/6 mice (8-week-old; systemic S. aureus-induced arthritis model) Dosage: 7.5 mg/per (combines with 25 μg/per anti-IL-15 antibodies) Administration: Intraperitoneal injection; twice daily from day 3 (after bacterial inoculation) and stopped at day 6. Result: Showed activities of reducing severe synovitis and bone erosions when combined with anti-IL-15 antibodies.